What is EOLS's market cap?

$493.40M, based on the Nov 4 close of $7.47.

Does Evolus pay a dividend?

No regular cash dividend has been paid in the last year.

How much of EOLS is sold short?

6.4M shares, 12.2% of float, as of Oct 15, 2026.

What sector is EOLS in?

Healthcare, in the Pharmaceuticals industry.

NASDAQ · EOLSHealthcarePharmaceuticals

Evolus, Inc. Common Stock (EOLS)

$7.47+1.36%

Close Nov 4, 2026 · split-adjusted

Nov 4, 2026$7.47▲ 16.54% in range

Nov 4, 2025Low $3.94 · High $9.30Nov 4, 2026

What changed · written from our data

As of Nov 4, 2026

Evolus closed at $7.47 on Nov 4, up 1.36%, 19.7% below its 52-week closing high. Volume of 849.8K shares was 1.22× its 20-day average (close to normal).

Split-adjusted performance: +1.2% over one month, +18.2% over six months, +16.9% over one year.

In the quarter ended Jun 30, 2026, revenue was $84.08M, up 21.2% from a year earlier, with a net margin of -9.6%.

Short interest was 6.4M shares at the Oct 15 settlement, up 13.9% from the prior report (12.2% of float, 7.1 days to cover).

Market cap$493.4M66.1M shares

Revenue · quarter$84.1M+21.2% YoY

Diluted EPS$-0.12—

P/E · TTM—P/S 1.6×

Net margin-9.6%Gross 68.0%

Dividend yieldNone

52-week range3.94 – 9.30−19.7% from high

Volume849.8K1.22× 20-day avg

Volatility · 60d48.9%Annualised

Short % of float12.2%7.1 days to cover

Net cash-$141.9MCash $45.2M

Next earnings—Not scheduled

Split-adjusted performance

1W −2.2%1M +1.2%3M +0.8%6M +18.2%YTD +12.3%1Y +16.9%3Y −1.8%5Y −1.2%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum81

Revenue growth67

Net margin63

Value (low P/E)—

Size61

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →

Shares short6.4M+13.9% vs prior

Days to cover7.1Settled Oct 15

% of float12.2%

Short vol. 10d60.3%of daily volume

Closest peers by size in Pharmaceuticals

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
EOLSEvolus	$7.47	+1.36%	+18.2%	+21.2%	−9.6%	—	$493.4M
MNPRMonopar Therapeutics	$72.81	+4.18%	+14.0%	—	—	—	$488.7M	Compare
ARVNArvinas	$7.42	+4.65%	−27.7%	+1014.7%	67.8%	52.2	$485.2M	Compare
AQSTAquestive Therapeutics	$3.80	−2.06%	−10.2%	+38.1%	−165.5%	—	$476.9M	Compare
CTMXCytomX Therapeutics	$2.35	+7.80%	−43.1%	−92.4%	−1457.4%	—	$512.1M	Compare
CBIOCrescent Biopharma	$13.82	+5.82%	−23.5%	—	—	—	$513.4M	Compare
FTHFaeth Therapeutics	$19.99	+1.73%	—	—	—	—	$516.6M	Compare
STTKShattuck Labs	$5.15	−5.85%	−22.9%	—	—	—	$516.9M	Compare
GYREGyre Therapeutics	$4.44	0.00%	−44.8%	−2.1%	−40.1%	—	$470.8M	Compare

News about Evolus

All news →

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Evolus, Inc. - EOLSGlobeNewswire Inc. · 1d ago▼ Negative

Quick answers

What does Evolus do?: Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels.
What is EOLS's market cap?: $493.40M, based on the Nov 4 close of $7.47.
Does Evolus pay a dividend?: No regular cash dividend has been paid in the last year.
How much of EOLS is sold short?: 6.4M shares, 12.2% of float, as of Oct 15, 2026.
What sector is EOLS in?: Healthcare, in the Pharmaceuticals industry.

About Evolus

Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.

HQ: Newport Beach, CA353 employeesListed Feb 8, 2018evolus.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology